---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-009233"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T22:24:58.532421+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%

## Summary
- Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
- GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).
- Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.
- 2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).
- Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies.

## SEC filing metadata
- accession: 0001628280-25-009233
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/0001628280-25-009233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/blfs-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-009233
- JSON: https://secwatch.observer/filing/0001628280-25-009233.json
- Plain text: https://secwatch.observer/filing/0001628280-25-009233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.